Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma
Medicina Clínica · 2024
DOI: 10.1016/j.medcli.2023.11.003 ↗Kurz gefasst
Leserbrief in der Zeitschrift Medicina Clínica, 2024. Verfasst von Thais Lizondo López und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Barcelona, Spain. Electronic address: tlizondo@clinic.cat. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Myocarditis, Liver Neoplasms, Myositis. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Barcelona, Spain. Electronic address: tlizondo@clinic.cat.
- Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Barcelona, Spain.
Zitieren
APA
Lizondo López, T., Carro Méndez, I., & Carcelero San Martín, E. (2024). Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma. Medicina Clínica. https://doi.org/10.1016/j.medcli.2023.11.003
Vancouver
Lizondo López T, Carro Méndez I, Carcelero San Martín E. Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma. Medicina Clínica. 2024. doi:10.1016/j.medcli.2023.11.003
BibTeX
@article{LizondoLpez2024,
author = {Lizondo López, Thais and Carro Méndez, Iria and Carcelero San Martín, Esther},
title = {Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma},
journal = {Medicina Clínica},
year = {2024},
doi = {10.1016/j.medcli.2023.11.003}
}
EUVIMED